회사 개요
EUDA Health Holdings Limited is a specialized entity engaged in delivering non-invasive healthcare solutions, specifically offering bioenergy capsules, stem cell therapy, CRISPR gene editing treatments, and dietary supplements alongside property management services. The company operates within the Real Estate sector and the Real Estate Services industry, a classification that reflects its dual focus on healthcare provision and asset management activities. As of the latest data, the company holds a market capitalization of $13.48M and reports annual revenue (TTM) of $5.16M, employing a workforce of 117 individuals. These financial figures indicate that EUDA functions as a small-cap enterprise with a relatively narrow revenue base compared to large-scale real estate operators, suggesting it occupies a niche position in the market where it leverages specialized medical services rather than traditional property development volume.
재무 건전성
The company reported a revenue of $5.16M over the trailing twelve months, yet this generated a net income of $-2,064,341, revealing a significant gap between top-line growth and profitability that points to a heavy cost structure or operational inefficiencies. This negative net income is further exacerbated by an EBITDA of $-1,992,526, indicating that the core operating business is currently burning cash before financing costs and tax considerations. Additionally, the free cash flow stands at $-3,350,164, which highlights a severe lack of financial flexibility as the company is unable to generate cash from operations to fund its own growth or debt obligations. Margin analysis shows a gross margin of 22.4%, which suggests a moderate ability to control direct costs, while the operating margin of -37.0% and profit margin of 5.2% indicate substantial overhead burdens and inconsistent bottom-line performance relative to revenue. On the balance sheet, the company holds cash of $176,584 against total debt of $2.28M, a disparity that signals a leveraged financial position despite the absence of a calculable debt-to-equity ratio due to negative equity. The current ratio of 0.23 further underscores precarious short-term liquidity, as current liabilities significantly exceed current assets, raising concerns about the ability to meet immediate obligations without external financing. Furthermore, the return on equity is listed as N/A due to the negative book value context, while the return on assets is -63.9%, demonstrating that management has not yet generated value from the asset base and is instead destroying shareholder and asset value through operations.
밸류에이션 평가
Valuation metrics for EUDA present a complex picture where the trailing P/E ratio of 17.83 contrasts sharply with a forward P/E of 4.46, implying that the market prices in a dramatic turnaround in earnings or that the current earnings are non-recurring and unsustainable. The price-to-book ratio of -3.57 indicates that the stock is trading at a deep discount relative to its net asset value, a phenomenon often seen in distressed or loss-making companies where the market does not value the assets at book price. Alternative valuation measures such as the price-to-sales ratio of 2.61 and an EV/EBITDA of -7.70 suggest that investors are pricing the company based on revenue potential rather than profitability, acknowledging that traditional earnings-based multiples are distorted by the current losses. Technical analysis shows a 52-week high of $86.00 and a 52-week low of $6.42, placing the current trading price significantly below the peak but above the floor, reflecting high volatility and uncertainty in the stock's valuation anchor. The beta value of 0.16 reveals that the stock exhibits very low price volatility relative to the broader market, moving in a range that is largely decoupled from general market indices, which may offer diversification benefits but also limits participation in broad market rallies.
Growth & Income
The company demonstrated robust revenue growth of 60.2% year-over-year, whereas earnings growth is listed as N/A due to the lack of comparable prior period earnings data, suggesting that the top-line expansion has not yet translated into profit yet. Unlike traditional dividend payers, EUDA does not distribute a dividend yield as it is N/A, nor does it maintain a payout ratio of 0.0% because the company retains all earnings, or in this case, absorbs all losses, to fund operations rather than return capital to shareholders. This reinvestment strategy is typical for early-stage or turnaround companies that prioritize expanding their healthcare service portfolio over immediate shareholder distributions. The overall growth and income profile indicates a high-risk, high-potential scenario where significant revenue expansion is being pursued despite substantial net losses, with no current income stream available to investors through dividends or stable earnings per share.